erythropoietin drug market Companies

ID: MRFR/Pharma/0852-HCR

85 Pages

Rahul Gotadki

October 2025

Erythropoietin (EPO) drugs companies specialize in the research, development, and manufacturing of medications that contain or mimic erythropoietin, a hormone responsible for stimulating red blood cell production. These drugs are commonly used in the treatment of anemia associated with various conditions, such as chronic kidney disease, cancer, and certain medical procedures.

Erythropoietin Drugs Market Research Report Forecast to 2035 Infographic

Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the erythropoietin drug market

Erythropoietin Drug Key Companies

Latest Erythropoietin Drug Companies Update

Johnson & Johnson Services, Inc. continues to hold a significant market share with its Procrit® and Epogen® brands, but faces competition from biosimilars like Amgen's Epoetin Alfa-NX and Teva's Epoetin alfa.

Roche is developing a new erythropoietin drug called Roxifilan for the treatment of anemia in patients with cancer.

Celltrion is expanding its presence in the market with its biosimilar erythropoietin drug Remsima®, which is approved for the treatment of several conditions, including anemia in cancer patients.

List of Erythropoietin Drug Key Companies in the Market

• Hoffmann-La Roche

• Johnson & Johnson

• Amgen

• Kyowa Hakko Kirin

• Intas Pharmaceuticals

• Teva Pharmaceutical Industries Ltd.

• Biocon

• Emcure Pharmaceuticals

• Celltrion Inc.

• Hospira